Clinical Trials open to enrollment

LIBImAb Study – Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or Bevacizumab

Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierosandro Tagliaferri
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)